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Abstract 
Ischaemic heart disease and cerebrovascular disease are among the leading causes of death 
in Australian men and women with heart diseases being the third highest cause of death in 
Australian women and fourth highest cause of death in Australian men (AIHW, 2006). In 
Australia more than 50% of all adults have two or three (out of a possible nine) risk factors 
for cardiovascular disease and 15% having four or more risk factors. 
 
It has long been recognised that diet modification can reduce these risks. Recently dietary 
advice has moved from an “exclusionary” to an “inclusionary” paradigm. That is, rather 
than identify dietary items to avoid, current guidelines recommend incorporating advice to 
increase the consumption of a range of functional foods including marine sourced omega-3 
fatty acids EPA and DHA and vegetable oils.   
 
EPA and DHA are effective functional foods in reducing CVD mortality, cardiac death, 
sudden death and myocardial infarction. EPA and DHA provide this cardiovascular benefit 
by improving several risk factors including: fasting plasma triglycerides, blood pressure 
and arterial compliance. However, a safety concern of dietary EPA and DHA 
supplementation is their capacity to cause a significant increase in LDL cholesterol 
concentrations.  
 
Dietary intake levels of EPA and DHA in the Australian diet are well below those 
associated with reductions in CVD risk. In 50% of the population a potential 20 – fold 
increase in EPA and DHA would be required to increase intake levels to those 
commensurate with reduced CVD risk.  
 
While dietary supplementation with EPA and DHA is one means of increasing dietary 
intake levels, strategies to increase the efficacy of EPA and DHA would also be 
advantageous and could reduce supplement doses. Dietary strategies that could 
simultaneously counteract the rise in LDL cholesterol caused by DHA would also be 
beneficial.  
 
 xiii
The research described in this thesis aimed to modify the bioavailability and cardiovascular 
effects of DHA by modifying other dietary factors and combining DHA with other active 
ingredients. To address these aims two human clinical trials were conducted. The first 
examined the effect of altering the types of oil and margarine consumed in the diet with 
view to reducing the dietary intake of omega-6 fatty acids while supplementing the diet 
with DHA-rich fish oil (MOFO study). This study showed that replacing usual dietary oil 
and margarine with canola products while supplementing the diet with 1.1g/d of DHA 
favourably improved total omega-3 fatty acid incorporation and reduced the omega-6: 
omega-3 fatty acid ratio in plasma and erythrocyte membrane phospholipids as effectively 
as double the supplement dose of DHA. Additionally, there was a similar rise in erythrocyte 
membrane and plasma DHA when either safflower or sunola oil, which contain very 
different amounts of linoleic acid, were consumed concurrently with a daily dietary 
supplementation of 1.1g/d of DHA. A distinguishing feature of canola is its relatively high 
omega-3 ALA content. Thus, these findings add to the body of scientific evidence 
supporting the view that the total amount of dietary omega-3 consumed has greater impact 
on the bioavailability of supplemented DHA than the ratio of dietary omega-6: omega-3 
fatty acids.  
 
The MOFO study also showed that the combination of canola plus 1.1g/d of DHA is 
equally as effective as daily supplementation with 2.2g/d of DHA at reducing fasting 
plasma triglyceride concentrations with the added benefit of preventing the significant rise 
in both LDL and total cholesterol caused by both doses of DHA alone. While further 
research is warranted based on the findings from animal studies, it can reasonably be 
proposed that the findings from the MOFO study may be an example of a synergistic effect 
of canola phytosterols and DHA, rather than ALA and DHA, working together to 
significantly reduce fasting plasma triglyceride concentrations while preventing detrimental 
effects on LDL cholesterol in people with mild hypertriglyceridemia.  
 
The second human clinical trial conducted as part of this thesis examined the effect of 
combining omega-3 fatty acids with soy isoflavones on fasting blood lipids, blood pressure 
and arterial compliance (Omega-Soy study). The Omega-Soy study showed that the 
 xiv
combined consumption of DHA with soy isoflavones resulted in an 8-10% improvement in 
HDL cholesterol, an 18-20% reduction in plasma triglyceride concentrations and the 
absence of a 10.8% rise in LDL cholesterol observed with DHA supplementation alone. 
Furthermore, the increases in LDL and total cholesterol observed with DHA 
supplementation in the first six weeks were reversed and significantly reduced when soy 
cereal was concurrently consumed. The results showed that the dietary combination of soy 
isoflavones and DHA improve the lipid profile of moderately hyperlipidemic individuals 
more favourably than either constituent alone.  
 
While further research is warranted based on evidence from in vitro cell culture and in vivo 
animal models demonstrating functional effects of soy isoflavones and DHA on lipid 
metabolism pathways, it can reasonably be proposed that the findings from the Omega-Soy 
study demonstrate a synergistic effect of soy isoflavones and DHA, working together to 
significantly reduce fasting plasma triglyceride concentrations without detrimental  effects 
on LDL cholesterol in people with mild hyperlipidemia.  
 
The findings from this thesis support two functional food synergies for effective 
improvement of blood lipid concentrations when consumed as part of the usual diet of men 
and postmenopausal women with moderately elevated blood lipids. These functional food 
combinations are DHA with canola and DHA with soy isoflavones. The findings of this 
thesis sheds some light on how isoflavones may be actively involved in reducing plasma 
cholesterol concentrations when consumed with soy protein or in soy containing foods, 
furthermore the findings of this thesis provide strategies for ultimately reducing the 
negative side effects of dietary DHA supplementation and for achieving a better outcome in 
overall lipid profile improvements than could be achieved with DHA supplementation 
alone. Future research into these synergistic combinations of functional food ingredients 
with DHA may lead to new directions in functional food development by food 
manufacturers to enable more consumers to manage their blood lipid concentrations with 
minimal or without drug therapy requirements.  
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